These findings suggest that blocking melanoma-PD-1 might contribute to the unprecedented efficacy of anti-PD-1 therapy. Two ligands for PD-1, designated PD-L1 and PD-L2, have been …

This review discusses the fundamental mechanisms of PD‐1 blockade, encompassing insights from T cells and B cells, and presents resistance to anti‐PD‐1 with a particular focus on …

PD-L1 is expressed on melanoma cells and the levels of PD-L1 expression positively correlate with higher ORR and longer PFS when patients are treated with anti-PD-1, while data about a …

Feb 24, 2023 · The U.S. Food and Drug Administration has approved two PD-1 inhibitors for melanoma. Keytruda ® (pembrolizumab) and Opdivo ® (nivolumab) turn on T-cells that boost …

Mar 1, 2023 · In a phase 1b, randomized trial involving 20 patients with stage III melanoma, neoadjuvant administration of the anti–PD-1 antibody nivolumab and the anti–CTLA-4 …

Mar 3, 2022 · Promising results in early clinical trials with PD-1 blocking antibodies in refractory solid tumors were confirmed in phase 3 studies in melanoma, where the PD-1 inhibitors …

Sep 10, 2015 · Therapeutic antibodies targeting programmed cell death 1 (PD-1) activate tumor-specific immunity and have shown remarkable efficacy in the treatment of melanoma. Yet, little …

Sep 20, 2016 · We hypothesized that PD-L1 and PD-L2 are more highly expressed in tumors with more prominent and diffuse T cell infiltration, and that they are markers of better prognosis for …

Aug 2, 2016 · Antibodies targeting programmed death 1 (PD-1) help prevent tumor cells from escaping immune-mediated destruction. We conducted this systematic review and meta …

Jul 11, 2013 · Two large, dose-escalation, phase 1 clinical trials evaluating the safety of the anti–PD-1 antibody nivolumab (formerly known as BMS936558) and the anti–PD-L1 antibody …